journal article·2008-03

Alendronate–hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells

Elisa Boanini, Paola Torricelli, Massimo Gazzano, Roberto Giardino, Adriana Bigi

Biomaterials· Volume 29· Issue 7
Publisher page

Abstract

The direct synthesis of hydroxyapatite in the presence of bisphosphonates is quite difficult due to the great affinity for calcium of these compounds, which are widely used in the treatment of pathologies related to bone loss. We recently developed a new method which allowed to synthesize alendronate-hydroxyapatite composite nanocrystals with a bisphosphonate content up to about 7 wt%. Herein we report the results of an in vitro study aimed to investigate the effects of alendronate incorporation into hydroxyapatite on bone cells response. Osteoblast-like MG63 cells and human osteoclasts were cultured on nanocrystals at different alendronate content (3.9, 6.2, 7.1 wt%). MG63 cells cultured on the composite nanocrystals display normal morphology, good proliferation and increased values of the differentiation parameters. In particular, when cultured on composites at relatively high alendronate contents, osteoblasts display increased values of alkaline phosphatase activity (ALP), collagen type I, and osteocalcin production, as well as significant decrease of matrix metalloproteinases (MMP-1 and MMP-13) production, with respect both to the control and to pure hydroxyapatite nanocrystals. It follows that the presence of alendronate enhances osteoblast activation and extracellular matrix mineralization processes, without any abnormal collagen degradation. The osteoclast number on the composite nanocrystals decrease indicating that the bisphosphonate exerts its inhibitory effect on osteoclast proliferation even when incorporated into hydroxyapatite.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Bone health and treatments · Bone health and osteoporosis research · Bone Metabolism and Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (27)

Show source-provided references
1. Fleisch · 2000
2. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis10.1359/JBMR.040325 ↗
3. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group10.1056/NEJM200102013440503 ↗
4. Recent advances in understanding the mechanism of action of bisphosphonates10.1016/j.coph.2006.03.005 ↗
5. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy10.1016/j.bone.2005.07.023 ↗
6. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite10.1016/j.bone.2005.05.003 ↗
7. Bisphosphonate actions: physical chemistry revisited10.1016/j.bone.2006.01.141 ↗
8. Determinants of structure–function relationships among bisphosphonates10.1016/j.bone.2007.03.002 ↗
9. Bisphosphonates: mechanisms of action10.1210/edrv.19.1.0325 ↗
10. Fractures after long-term alendronate therapy [Letter]10.1210/jcem.86.4.7436-1 ↗
11. Long-term safety of bisphosphonates10.1210/jc.2005-0057 ↗
12. Composite nanocrystals provide new insight on alendronate interaction with hydroxyapatite structure10.1002/adma.200602497 ↗
13. Profile analysis of X-ray diffraction data from powder polymer samples
14. Spectrophotometric determination of alendronate in pharmaceutical formulations via complex formation with Fe(III) ions10.1016/S0731-7085(02)00021-3 ↗
15. Bisphosphonates: pharmacology, mechanism of action and clinical uses10.1007/PL00004164 ↗
16. Inhibition of bone resorption by bisphosphonates, osteoclasts, and bone10.1007/BF02555852 ↗
17. Cellular and molecular mechanisms of action of biphosphonates10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L ↗
18. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure10.1172/JCI115539 ↗
19. Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro10.1002/(SICI)1097-4644(19990915)74:4<616::AID-JCB11>3.0.CO;2-Q ↗
20. Effects of α-TCP and TetCP on MC3T3-E1 proliferation, differentiation and mineralization10.1016/S0142-9612(02)00411-8 ↗
21. Relationship between collagen synthesis and expression of the osteoblast phenotype in MC3T3-E1 cells10.1002/jbmr.5650070216 ↗
22. Mineralization and the expression of matrix proteins during in vivo bone development10.1007/s002239900397 ↗
23. In vitro behaviour of osteoblasts cultured on orthopaedic biomaterials with different surface roughness, uncoated and fluorohydroxyapatite-coated, relative to the in vivo osteointegration rate10.1177/039139880302600611 ↗
24. Proliferation and differentiation rates of a human osteoblast-like cell line (SaOS-2) in contact with different bone substitute materials10.1002/1097-4636(200110)57:1<132::AID-JBM1152>3.0.CO;2-K ↗
25. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression10.1038/emm.2002.21 ↗
26. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients10.1007/s00198-005-0035-4 ↗
27. MMP inhibition and downregulation by bisphosphonates10.1111/j.1749-6632.1999.tb07702.x ↗